Literature DB >> 8461968

Familial Alzheimer's disease. A pedigree with a mis-sense mutation in the amyloid precursor protein gene (amyloid precursor protein 717 valine-->glycine).

A M Kennedy1, S Newman, A McCaddon, J Ball, P Roques, M Mullan, J Hardy, M C Chartier-Harlin, R S Frackowiak, E K Warrington.   

Abstract

Ten affected individuals are described from a kindred with autosomal dominant familial Alzheimer's disease in which a mutation in the amyloid precursor protein gene results in a valine to glycine substitution at amyloid precursor protein 717 which co-segregates with the disease. The mean age at onset of symptoms was 52 years with a range from 40 years to 67 years. The median duration of the disease was 11 years, with a range of 7-16 years. All individuals fulfilled the National Institute for Neurological and Communicative Disorders and Stroke criteria for probable Alzheimer's disease. A homogeneous clinical and neuropsychological pattern was evident within the family. Myoclonic jerks, seizures, depression and a lack of insight were common features. Positron emission tomography demonstrated biparietal bitemporal hypometabolism in the one affected individual who was studied. The diagnosis was confirmed histopathologically in one individual.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461968     DOI: 10.1093/brain/116.2.309

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  14 in total

1.  Neuropsychological function in nondemented carriers of presenilin-1 mutations.

Authors:  J M Ringman; C Diaz-Olavarrieta; Y Rodriguez; M Chavez; L Fairbanks; F Paz; A Varpetian; H C Maldonado; M A Macias-Islas; J Murrell; B Ghetti; C Kawas
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

Review 2.  Beta-secretase: structure, function, and evolution.

Authors:  Chitra Venugopal; Christina M Demos; K S Jagannatha Rao; Miguel A Pappolla; Kumar Sambamurti
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

3.  Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide.

Authors:  M A Pappolla; M Sos; R A Omar; R J Bick; D L Hickson-Bick; R J Reiter; S Efthimiopoulos; N K Robakis
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

4.  Neuronal Network Excitability in Alzheimer's Disease: The Puzzle of Similar versus Divergent Roles of Amyloid β and Tau.

Authors:  Syed Faraz Kazim; Joon Ho Seo; Riccardo Bianchi; Chloe S Larson; Abhijeet Sharma; Robert K S Wong; Kirill Y Gorbachev; Ana C Pereira
Journal:  eNeuro       Date:  2021-04-23

Review 5.  Network abnormalities and interneuron dysfunction in Alzheimer disease.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Nat Rev Neurosci       Date:  2016-11-10       Impact factor: 34.870

Review 6.  Correlating familial Alzheimer's disease gene mutations with clinical phenotype.

Authors:  Natalie S Ryan; Martin N Rossor
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 7.  The role of beta-amyloid in the development of Alzheimer's disease.

Authors:  K Ii
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

8.  Molecular pathology of Alzheimer's disease.

Authors:  M N Rossor
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

Review 9.  The role of beta-amyloid peptide in Alzheimer's disease.

Authors:  A LeBlanc
Journal:  Metab Brain Dis       Date:  1994-03       Impact factor: 3.584

10.  The earliest cognitive change in a person with familial Alzheimer's disease: presymptomatic neuropsychological features in a pedigree with familial Alzheimer's disease confirmed at necropsy.

Authors:  S K Newman; E K Warrington; A M Kennedy; M N Rossor
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.